SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
KZIA
--
0.00%
--
Kazia Therapeutics Shares Volatile Following Press Release Highlighting Paxalisib Phase 2 Data At ASCO
Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly
Benzinga · 5d ago
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
PR Newswire · 5d ago
Iain Ross Is The Independent Chairman of the Board of Kazia Therapeutics Limited (ASX:KZA) And They Just Picked Up 19% More Shares
Simply Wall St. · 05/29 21:34
Did You Manage To Avoid Kazia Therapeutics' (ASX:KZA) Devastating 86% Share Price Drop?
Simply Wall St. · 05/25 05:49
Kazia Therapeutics up 18% premarket on positive paxalisib data
Seeking Alpha - Article · 04/08 12:46
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
PR Newswire · 04/07 13:00
Is Kazia Therapeutics Limited's (ASX:KZA) CEO Paid At A Competitive Rate?
Simply Wall St. · 02/24 21:34
Edison issues ADR update on Kazia Therapeutics (KZIA)
ACCESSWIRE · 01/13 12:55
SBGL, OLLI among premarket gainers
Seeking Alpha - Article · 12/11/2019 14:11
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
PR Newswire · 12/11/2019 00:41
Edison issues ADR outlook on Kazia Therapeutics (KZIA)
ACCESSWIRE · 12/02/2019 13:45
If You Had Bought Kazia Therapeutics (ASX:KZA) Shares A Year Ago You'd Have Made 60%
Simply Wall St. · 11/28/2019 22:12
ABEO, HEPA, EVH and KZIA among midday movers
Seeking Alpha - Article · 11/27/2019 17:42
NTNX, DLTR, VSTM and AKER among midday movers
Seeking Alpha - Article · 11/26/2019 17:42
ARWR, KL, ADMP and SRNE among midday movers
Seeking Alpha - Article · 11/25/2019 17:41
Kazia Therapeutics Reports Interim Data From Ongoing Phase 2 Study Of GDC-0084 In Glioblastoma
Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the
Benzinga · 11/25/2019 15:00
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
PR Newswire · 11/24/2019 23:00
Kazia Announces Positive Interim Efficacy Data From GDC-0084 Phase Ii Studyin Glioblastoma Released at SNO Conference
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to share with investorsinterim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most commonand most aggressive form of primary brain cancer.
Benzinga · 11/24/2019 22:22
Kazia Therapeutics up 83%
seekingalpha · 11/21/2019 01:52
Kazia Raises A$4.0 Million to Progress R&D Programs
PR Newswire · 10/28/2019 03:16